Evidence map›Paper›PMID 24932692›Full record

ArticlePloS one2014

Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.

Rodrigo Maciel da Costa Godinho, Flavio Lemos Matassoli, Carolina Gonçalves de Oliveira Lucas, Paula Ordonhez Rigato, Jorge Luiz Santos Gonçalves, Maria Notomi Sato, Milton Maciel, Ligia Maria Torres Peçanha, J Thomas August, Ernesto Torres de Azevedo Marques and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Rodrigo Maciel da Costa GodinhoDepartamento de Virologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Flavio Lemos MatassoliDepartamento de Virologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Carolina Gonçalves de Oliveira LucasDepartamento de Virologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Paula Ordonhez RigatoLaboratorio de Dermatologia e Imunodeficiencias, LIM-56, Departamento de Dermatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Jorge Luiz Santos GonçalvesDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Maria Notomi SatoLaboratorio de Dermatologia e Imunodeficiencias, LIM-56, Departamento de Dermatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Milton MacielEnteric Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, Maryland, United States of America; Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Ligia Maria Torres PeçanhaDepartamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
J Thomas AugustDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America.
Ernesto Torres de Azevedo MarquesDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, Baltimore, Maryland, United States of America; Department of Infectious Diseases and Microbiology, Center for Vaccine Research, Pittsburgh, Pennsylvania, United States of America; Departamento de Virologia, Fiocruz - Pernambuco, Recife, Brazil.
Luciana Barros de ArrudaDepartamento de Virologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Universidade Federal do Rio de Janeiro · BRJohns Hopkins Medicine · USUniversidade de São Paulo · BRFundação Oswaldo Cruz · BR

Funding

HIV-1 Gene Products/Targeted/MHC II Antigen PresentationR37AI041908 · NIAID · JOHNS HOPKINS UNIVERSITY · PI AUGUST, J. THOMAS · 2002 to 2011
$4.1M
MECHANISMS TO ENHANCE CYTOLYTIC T CELL RESPONSES TO HIVR21AI044317 · NIAID · JOHNS HOPKINS UNIVERSITY · PI AUGUST, J. THOMAS THOMAS · 1998 to 1999
–
NIAID NIH HHS R21-AI44317NIAID NIH HHS R37 AI041908NIAID NIH HHS R37-AI41908
6 · The paper itself

Abstract

We have previously demonstrated that a DNA vaccine encoding HIV-p55gag in association with the lysosomal associated membrane protein-1 (LAMP-1) elicited a greater Gag-specific immune response, in comparison to a DNA encoding the native gag. In vitro studies have also demonstrated that LAMP/Gag was highly expressed and was present in MHCII containing compartments in transfected cells. In this study, the mechanisms involved in these processes and the relative contributions of the increased expression and altered traffic for the enhanced immune response were addressed. Cells transfected with plasmid DNA constructs containing p55gag attached to truncated sequences of LAMP-1 showed that the increased expression of gag mRNA required p55gag in frame with at least 741 bp of the LAMP-1 luminal domain. LAMP luminal domain also showed to be essential for Gag traffic through lysosomes and, in this case, the whole sequence was required. Further analysis of the trafficking pathway of the intact LAMP/Gag chimera demonstrated that it was secreted, at least in part, associated with exosome-like vesicles. Immunization of mice with LAMP/gag chimeric plasmids demonstrated that high expression level alone can induce a substantial transient antibody response, but targeting of the antigen to the endolysosomal/secretory pathways was required for establishment of cellular and memory response. The intact LAMP/gag construct induced polyfunctional CD4+ T cell response, which presence at the time of immunization was required for CD8+ T cell priming. LAMP-mediated targeting to endolysosomal/secretory pathway is an important new mechanistic element in LAMP-mediated enhanced immunity with applications to the development of novel anti-HIV vaccines and to general vaccinology field.

Indexed as

Secretory PathwayAnimalsCD4-Positive T-LymphocytesEndosomesExosomesFemalegag Gene Products, Human Immunodeficiency VirusHEK293 CellsHumansImmunizationLymphocyte ActivationLysosomal-Associated Membrane Protein 1LysosomesMice, Inbred BALB CProtein Structure, TertiaryProteolysisgag Gene Products, Human Immunodeficiency VirusLysosomal-Associated Membrane Protein 1RNA, Messenger

Identifiers

PMID24932692
PMCPMC4059647
OpenAlexW2094788348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.